|Classification and external resources|
Hepatoblastoma is an uncommon malignant liver neoplasm occurring in infants and children and composed of tissue resembling fetal liver cells, mature liver cells, or bile duct cells. They usually present with an abdominal mass. The disease is most commonly diagnosed during a child's first three years of life Alpha-fetoprotein (AFP) commonly is elevated, but when AFP is not elevated at diagnosis the prognosis is poor.
Patients with familial adenomatous polyposis (FAP), a syndrome of early-onset colonic polyps and adenocarcinoma, frequently develop hepatoblastomas. Also beta-catenin mutations have been shown to be common in sporadic hepatoblastomas, occurring in as many as 67% of patients.
One study suggests that low birth weight might be a risk factor for hepatoblastoma.
A Children's Cancer Group study by Buckley et al. (1989) found significant linkage between hepatoblastoma and maternal and paternal exposure to metals.
The most common method of testing for hepatoblastoma is to a blood test checking the Alpha-fetoprotein. Alpha-fetoprotein (AFP) is used as a biomarker to help determine the presence of liver cancer in children. At birth, infants have relatively high levels of AFP, which fall to normal adult levels by the first year of life. The Normal levels for AFP in children has been reported as lower than 50 nanograms per milliliter (ng/ml) and 10 ng/ml. AFP Blood Test AFP greater than 500 (ng/ml) is a significant indicator of hepatoblastoma. AFP is also used as an indicator of the success of treatments. If treatments are successful in removing the cancer it can be expected that AFP levels will fall back to normal.
Surgical resection, adjuvant chemotherapy prior to resection, and liver transplantation have been used to treat these neoplasms, primary transplantation provides high, long term, disease-free survival rate in the range of 80%, in cases of complete resection and adjuvant chemotherapy survival rates approach 100%. The presence of metastases is the most potent predictor of poor prognosis.
- De Ioris M, Brugieres L, Zimmermann A, Keeling J, Brock P, Maibach R, Pritchard J, Shafford L, Zsiros J, Czaudzerna P, Perilongo G (2007). "Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: The SIOPEL group experience.". Eur J Cancer 44 (4): 545. doi:10.1016/j.ejca.2007.11.022. PMID 18166449.
- Hirschman BA, Pollock BH, Tomlinson GE (August 2005). "The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds". J. Pediatr. 147 (2): 263–6. doi:10.1016/j.jpeds.2005.04.019. PMID 16126064.
- Sanders RP, Furman WL (November 2006). "Familial adenomatous polyposis in two brothers with hepatoblastoma: implications for diagnosis and screening". Pediatr Blood Cancer 47 (6): 851–4. doi:10.1002/pbc.20556. PMID 16106429.
- Anna CH, Sills RC, Foley JF, Stockton PS, Ton TV, Devereux TR (June 2000). "Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam". Cancer Res. 60 (11): 2864–8. PMID 10850429.
- Tan X, Apte U, Micsenyi A, et al. (July 2005). "Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver". Gastroenterology 129 (1): 285–302. doi:10.1053/j.gastro.2005.04.013. PMC 1821080. PMID 16012954.
- Koch A, Waha A, Hartmann W, et al. (June 2005). "Elevated expression of Wnt antagonists is a common event in hepatoblastomas". Clin. Cancer Res. 11 (12): 4295–304. doi:10.1158/1078-0432.CCR-04-1162. PMID 15958610.
- Ruck P, Xiao JC (November 2002). "Stem-like cells in hepatoblastoma". Med. Pediatr. Oncol. 39 (5): 504–7. doi:10.1002/mpo.10175. PMID 12228907.
- Tanimura M, Matsui I, Abe J, et al. (July 1998). "Increased risk of hepatoblastoma among immature children with a lower birth weight". Cancer Res. 58 (14): 3032–5. PMID 9679968.
- Tim, P, et al.. "Hepatoblastoma".
- Ang JP, Heath JA, Donath S, Khurana S, Auldist A (February 2007). "Treatment outcomes for hepatoblastoma: an institution's experience over two decades". Pediatr. Surg. Int. 23 (2): 103–9. doi:10.1007/s00383-006-1834-1. PMID 17119981.
- Otte JB, Pritchard J, Aronson DC, et al. (January 2004). "Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience". Pediatr Blood Cancer 42 (1): 74–83. doi:10.1002/pbc.10376. PMID 14752798.
- Otte JB, de Ville de Goyet J, Reding R (October 2005). "Liver transplantation for hepatoblastoma: indications and contraindications in the modern era". Pediatr Transplant 9 (5): 557–65. doi:10.1111/j.1399-3046.2005.00354.x. PMID 16176410.
- Czauderna P, Mackinlay G, Perilongo G, et al. (June 2002). "Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group". J. Clin. Oncol. 20 (12): 2798–804. doi:10.1200/JCO.2002.06.102. PMID 12065556.
- humpath #2775 (Pathology images)
- University of Minnesota hepatoblastoma epidemiology study
- What is Hepatoblastoma?